Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Dov Bergwerk is Interim Chief Legal Officer at Teva Pharmaceutical Industries. OQRO lists 7 transactions filed with the SEC under this name, the latest on Nov 12, 2026, each linked to the official Form 4.
Interim Chief Legal Officer
Disclosures on record
7
Companies involved
1
As of the latest filing on , Dov Bergwerk reported holding 11,943 shares of Teva Pharmaceutical Industries (TEVA), worth about $531K at the last close of $45 (Nov 13, 2026). In the last 12 months, Dov Bergwerk sold $1.1M in 2 sales.
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Teva Pharmaceutical Industries TEVA | 11,943 | 12K direct | $45 | $531K | Nov 4, 2026 |
Is this Dov Bergwerk’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
Teva Pharmaceutical IndustriesTEVA
7 disclosures · Nov 2026 · 2 sold
Nov 10, 20269,433disclosed Nov 12
DetailsOfficial recordNov 4, 2026Sold~$730Kdisclosed Nov 6
DetailsOfficial recordNov 4, 2026Sold~$365Kdisclosed Nov 6
DetailsOfficial recordNov 4, 20268,755disclosed Nov 6
DetailsOfficial recordNov 4, 20268,755disclosed Nov 6
DetailsOfficial recordNov 4, 202618Kdisclosed Nov 6
DetailsOfficial recordNov 4, 202618Kdisclosed Nov 6
DetailsOfficial recordDov Bergwerk reported 0 open-market purchases and 2 sales here, 2026.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
Dov Bergwerk has no open-market purchase on record since 2026. Sales in 1 of the 1 years since 2026.
Dov Bergwerk reported 0 open-market purchases and 2 sales since 2026; no open-market purchase.
| Year | Bought | Sold |
|---|---|---|
| 2026 | — | $1.1M2×2 trades |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the latest SEC Form 4, dated Nov 4, 2026, Dov Bergwerk reported holding 11,943 shares of Teva Pharmaceutical Industries (TEVA). At the last close of $45 on Nov 13, 2026, that is about $531K. This is the stake disclosed in filings, not a net worth.
In SEC filings of the last 12 months, Dov Bergwerk reported 2 open-market sales worth $1.1M, and no open-market purchase. Shares withheld for taxes, gifts and option exercises are not counted in these totals.
Dov Bergwerk has no open-market purchase on record since 2026. Sales in 1 of the 1 years since 2026.
In SEC filings since 2026: no open-market purchase is on record; the latest open-market sale is from 2026.
Teva Pharmaceutical Industries (TEVA), from 2026 to 2026: 0 purchases and 2 sales.
